Canadian-based drug development firm Sierra Oncology has received clearance from the UK regulatory authorities to amend two of its ongoing Phase I clinical trials of SRA737 within the country.

SRA737 is a potent, orally bio-available, highly selective, small molecule checkpoint kinase 1 (Chk1) inhibitor.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The amended Phase I trial of SRA737 as a monotherapy will assess the product's preliminary efficacy in addition to the originally planned evaluation of the safety and tolerability.

The trial will now include a cohort expansion phase simultaneously with a dose expansion phase.

While the dose expansion phase will examine increasing doses of SRA737, the cohort expansion phase will recruit patients with genetically defined tumours that have genomic alterations.

"While the dose expansion phase will examine increasing doses of SRA737, the cohort expansion phase will recruit patients with genetically defined tumours that have genomic alterations."

The cohort expansion phase will involve patients with colorectal cancer, ovarian cancer, castration-resistant prostate cancer, non-small-cell lung cancer, and head and neck squamous cell carcinoma.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Sierra Oncology president and CEO Dr Nick Glover said: "Collaborating closely with our investigators and The Institute of Cancer Research, London, and The Royal Marsden in the UK, we have designed significant enhancements to our ongoing clinical trials for SRA737, which can now be implemented immediately and that are intended to enrich these studies with patients we believe are promising candidates for treatment with our drug."

Alongside the determination of safety profile, maximum tolerated dose (MTD) and recommended dose, the other Phase I trial of SRA737 in combination with gemcitabine will also evaluate the preliminary efficacy.

A stage 2 dose escalation phase and a cohort expansion phase is now being added to the trial, which also includes a stage 1 dose escalation phase.

The trial is being carried out for the treatment of patients with bladder cancer and pancreatic cancer.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact